Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

UFH is the Most Used Anticoagulant in Hemodialysis, Decreasing the Risk of Clot Formation in the Circuit.

NCT05148377 is registered in ClinicalTrials.gov with Eurofarma Laboratorios S.A. as lead sponsor.

NCT NCT05148377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05148377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
UFH is the Most Used Anticoagulant in Hemodialysis, Decreasing the Risk of Clot Formation in the Circuit.
Lead sponsor
Eurofarma Laboratorios S.A.
Phase
Phase 3
Overall status
Completed
Start date
August 1, 2007
Completion date
December 1, 2008
Enrollment
128 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hemodialysis complication